MX2018011836A - Conjugados de anticuerpo farmaco anti-cd70. - Google Patents

Conjugados de anticuerpo farmaco anti-cd70.

Info

Publication number
MX2018011836A
MX2018011836A MX2018011836A MX2018011836A MX2018011836A MX 2018011836 A MX2018011836 A MX 2018011836A MX 2018011836 A MX2018011836 A MX 2018011836A MX 2018011836 A MX2018011836 A MX 2018011836A MX 2018011836 A MX2018011836 A MX 2018011836A
Authority
MX
Mexico
Prior art keywords
drug conjugates
antibody drug
antibodies
amino acid
naturally
Prior art date
Application number
MX2018011836A
Other languages
English (en)
Inventor
Richard S Barnett
Nick Knudsen
Amha Hewet
Jason K Pinkstaff
Sandra Biroc
Timothy Buss
Tsotne Javahishvili
Shailaja Srinagesh
Damien Bresson
Ying Sun
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of MX2018011836A publication Critical patent/MX2018011836A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Esta invención se refiere a anticuerpos anti-CD70 y a conjugados de anticuerpo fármaco que comprenden al menos un aminoácido codificado de manera no natural. Se describen en la presente anticuerpos aCD70 con uno o más aminoácidos codificados de manera no natural y además se describen conjugados de anticuerpo fármaco en donde los anticuerpos aCD70 de la invención se conjugan a una o más toxinas. Además se describen métodos para utilizar tales conjugados de anticuerpo fármaco de aminoácidos no naturales, incluyendo usos terapéuticos, de diagnóstico, y otros de biotecnología.
MX2018011836A 2012-06-19 2014-12-18 Conjugados de anticuerpo farmaco anti-cd70. MX2018011836A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261661782P 2012-06-19 2012-06-19

Publications (1)

Publication Number Publication Date
MX2018011836A true MX2018011836A (es) 2020-09-14

Family

ID=48700005

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014015878A MX359449B (es) 2012-06-19 2013-06-19 Conjugados de anticuerpo fármaco anti-cd70.
MX2018011836A MX2018011836A (es) 2012-06-19 2014-12-18 Conjugados de anticuerpo farmaco anti-cd70.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014015878A MX359449B (es) 2012-06-19 2013-06-19 Conjugados de anticuerpo fármaco anti-cd70.

Country Status (13)

Country Link
US (3) US10208123B2 (es)
EP (2) EP3488870B1 (es)
JP (3) JP6343609B2 (es)
KR (3) KR102190832B1 (es)
CN (2) CN104619351B (es)
AU (1) AU2013277169B2 (es)
CA (1) CA2877124A1 (es)
ES (1) ES2712648T3 (es)
IL (1) IL236323B (es)
MX (2) MX359449B (es)
NZ (2) NZ724593A (es)
SG (1) SG11201408494UA (es)
WO (1) WO2013192360A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE045845T2 (hu) 2010-08-17 2021-12-28 Ambrx Inc Módosított relaxin polipeptidek és felhasználásuk
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US9981046B2 (en) 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
AU2013277169B2 (en) 2012-06-19 2017-02-02 Ambrx, Inc. Anti-CD70 antibody drug conjugates
MY174813A (en) 2013-03-15 2020-05-16 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
AU2014337317A1 (en) 2013-10-15 2016-09-15 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
US10675355B2 (en) 2013-12-27 2020-06-09 Var2 Pharmaceuticals Aps VAR2CSA-drug conjugates
CA2935077C (en) 2013-12-27 2022-03-15 Geoffrey C. Winters Sulfonamide-containing linkage systems for drug conjugates
SI3134124T1 (sl) 2014-04-25 2019-06-28 Pierre Fabre Medicament Konjugat protitelesa zdravila IGF-1R in uporaba le-tega za zdravljenje raka
MX2016013999A (es) 2014-04-25 2017-05-30 Pf Medicament Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
US10391168B1 (en) * 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
DK3194421T3 (da) 2014-09-17 2022-02-14 Zymeworks Inc Cytotoksiske og antimitotiske forbindelser samt fremgangsmåder til anvendelse heraf
EP3226909A1 (en) * 2014-12-03 2017-10-11 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
JP6871858B2 (ja) 2015-01-28 2021-05-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗体薬物コンジュゲート
JP6607634B2 (ja) * 2015-09-04 2019-11-20 学校法人 岩手医科大学 腫瘍の再発を抑制するための標的分子としてのｔａｆ１５遺伝子およびその産物
US10618935B2 (en) 2015-11-03 2020-04-14 Industrial Technology Research Institute Antibody-drug conjugate (ADC) and method for forming the same
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
LT3423105T (lt) 2016-03-02 2021-09-10 Eisai R&D Management Co., Ltd. Antikūno-vaisto konjugatai eribulino pagrindu ir jų panaudojimo būdai
CA3052639A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CN117286182A (zh) 2017-06-02 2023-12-26 Ambrx公司 促进含非天然氨基酸的蛋白质产生的方法和组合物
CN108404138B (zh) * 2018-03-09 2020-04-17 中国药科大学 一种靶向cd24单克隆抗体与二乙胺偶氮鎓二醇盐的偶联物及其应用
JP2020019723A (ja) * 2018-07-30 2020-02-06 国立大学法人 鹿児島大学 抗ＣＤ７０抗体とＩｇＧ結合ペプチドの複合体
CN109232712B (zh) * 2018-08-21 2021-08-03 联宁（苏州）生物制药有限公司 一种用于抗体药物偶联物的中间体的制备方法
CN111417655A (zh) 2018-08-28 2020-07-14 润俊(中国)有限公司 抗cd3抗体叶酸生物偶联物及其用途
CN109799352B (zh) * 2019-01-29 2022-03-08 北京健坤禾润科技有限公司 化学发光试剂及其在免疫检测中应用
WO2020256721A1 (en) * 2019-06-19 2020-12-24 Synthis, Llc Antib0dy-alk5 inhibitor conjugates and their uses
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
WO2023000171A1 (zh) * 2021-07-20 2023-01-26 浙江新码生物医药有限公司 一种含有抗her2-药物偶联物的冻干组合物、冻干制剂及其制备方法和用途
CN113754769B (zh) 2021-10-13 2023-06-06 宜明昂科生物医药技术（上海）股份有限公司 靶向cd70的抗体及其制备和用途
CN116023500B (zh) * 2021-10-25 2023-07-04 重庆精准生物技术有限公司 一种靶向全人源化cd70的嵌合抗原受体及其应用
WO2024077277A1 (en) 2022-10-07 2024-04-11 Ambrx, Inc. Drug linkers and antibody conjugates thereof
CN115708810A (zh) * 2022-11-03 2023-02-24 浙江新码生物医药有限公司 含有抗cd70-药物偶联物的冻干组合物、冻干制剂及其制备方法和用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
CA2282504A1 (en) 1997-02-25 1998-08-27 Jun-Ping Xu Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
ATE279430T1 (de) 1998-03-05 2004-10-15 Chiron Corp Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP2005502322A (ja) 2001-04-19 2005-01-27 ザ スクリップス リサーチ インスティテュート 非天然アミノ酸のインビボ組込み
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
EP1583816A4 (en) 2002-12-22 2007-06-13 Scripps Research Inst PROTEIN NETWORKS
JP5356648B2 (ja) * 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
WO2006113909A2 (en) * 2005-04-19 2006-10-26 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
ES2545533T3 (es) 2004-11-01 2015-09-11 The Regents Of The University Of California Composiciones y métodos para modificación de biomoléculas
JP5425398B2 (ja) 2004-12-22 2014-02-26 アンブレツクス・インコーポレイテツド 非天然アミノ酸及びポリペプチドを含む組成物、非天然アミノ酸及びポリペプチドに関連する方法並び非天然アミノ酸及びポリペプチドその使用
CN108047086B (zh) * 2004-12-22 2023-06-16 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及其用途
EP1934261B1 (en) 2005-09-26 2014-10-29 Medarex, L.L.C. Human monoclonal antibodies to cd70
WO2008074004A2 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
CN101605906A (zh) * 2006-12-14 2009-12-16 梅达雷克斯公司 结合cd70的人类抗体及其用途
JP2010512800A (ja) * 2006-12-18 2010-04-30 アンブルックス，インコーポレイテッド 非天然のアミノ酸およびポリペプチドを含んでいる組成物、これらが関連する方法、ならびにこれらの利用
US20100226987A1 (en) * 2007-06-28 2010-09-09 Capsutech Ltd. Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
MX371526B (es) * 2011-05-27 2020-01-31 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
MX359217B (es) * 2011-05-27 2018-09-19 Ambrx Inc Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales.
WO2013068874A1 (en) * 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
SG11201408153YA (en) 2012-06-07 2015-01-29 Ambrx Inc Prostate-specific membrane antigen antibody drug conjugates
AU2013277169B2 (en) 2012-06-19 2017-02-02 Ambrx, Inc. Anti-CD70 antibody drug conjugates
CN104755510B (zh) 2012-07-14 2017-11-07 印度石油有限公司 包含1,2‑亚苯基二酯作为内部供体的齐格勒‑纳塔催化剂系统及其制备方法
US9796854B1 (en) * 2016-07-07 2017-10-24 Intuitive Surgical Operations, Inc. Method of synthesizing near IR, closed chain sulfo-cyanine dyes

Also Published As

Publication number Publication date
US20230295320A1 (en) 2023-09-21
WO2013192360A1 (en) 2013-12-27
SG11201408494UA (en) 2015-02-27
CN104619351B (zh) 2020-01-21
JP7183215B2 (ja) 2022-12-05
IL236323A0 (en) 2015-02-26
EP3488870B1 (en) 2024-03-20
AU2013277169A1 (en) 2015-01-29
EP2861262A1 (en) 2015-04-22
JP6343609B2 (ja) 2018-06-13
KR20210148388A (ko) 2021-12-07
NZ724593A (en) 2019-05-31
KR20200140399A (ko) 2020-12-15
JP2018168155A (ja) 2018-11-01
EP3488870A1 (en) 2019-05-29
US20190338039A1 (en) 2019-11-07
JP2020143151A (ja) 2020-09-10
CN111499684A (zh) 2020-08-07
JP6756774B2 (ja) 2020-09-16
MX359449B (es) 2018-09-28
CN104619351A (zh) 2015-05-13
KR102490719B1 (ko) 2023-01-19
KR102190832B1 (ko) 2020-12-15
NZ703581A (en) 2016-09-30
IL236323B (en) 2020-11-30
US10208123B2 (en) 2019-02-19
KR20150032716A (ko) 2015-03-27
CA2877124A1 (en) 2013-12-27
KR102332435B1 (ko) 2021-12-01
US20150141624A1 (en) 2015-05-21
MX2014015878A (es) 2015-08-14
EP2861262B1 (en) 2018-11-28
US11459392B2 (en) 2022-10-04
JP2015523359A (ja) 2015-08-13
ES2712648T3 (es) 2019-05-14
AU2013277169B2 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
MX2018011836A (es) Conjugados de anticuerpo farmaco anti-cd70.
MX2019002732A (es) Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
CY1123404T1 (el) Αντι-girt αντισωματα
WO2014062697A3 (en) Drug delivery conjugates containing unnatural amino acids and methods for using
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
BR112019008854A2 (pt) ligantes contendo peptídeo para conjugados de anticorpo-fármaco
EA201390940A1 (ru) Материалы и способы конъюгирования водорастворимого производного жирной кислоты с белком
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
BR112015004022A2 (pt) aminoácidos modificados compreendendo um grupo azido
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
EA201890389A3 (ru) Композиции конъюгата xten и способы их получения
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
NZ630542A (en) Methods of treating a tauopathy
WO2011113019A3 (en) Ctla4 proteins and their uses
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
BR112012032778A2 (pt) "proteínas multiespecíficas e multivalentes"
EP4276180A3 (en) Clostridium histolyticum enzyme
TR201903066T4 (tr) E. colı'de enzimatik konjugasyonla rekombinant aşı üretimi.
EA201690782A1 (ru) Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты
WO2013177593A3 (en) Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
UA107836C2 (uk) Метод лікування хвороби альцгеймера
WO2014179184A8 (en) Compositions for inducing immune tolerance to coagulation factor proteins
CL2015001849A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpos fármaco, y usos de estos
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы